Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

Original reporting
Published Nov 7, 2026, 12:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$COLL
Neutral
high confidence
Mentioned
$COLL
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$COLLNeutralMed
01

Why it matters

The earnings beat on revenue and strong guidance may attract buying, but GAAP earnings decline could limit upside.

02

Market read

Earnings release provides fresh data on growth drivers and profitability, influencing investor sentiment in the biotech sector.

03

What to watch

Potential BELBUCA generic launch risk and high Azstarys gross-to-net may erode future cash flow.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Collegium Pharmaceutical reported Q3 results, highlighted ADHD product growth, and reaffirmed 2026 guidance while noting pain portfolio pressures.

Company-level read

Ticker impact

$COLLNeutralHigh confidence
Context

Q3 earnings call disclosed record $216.3M revenue, ADHD growth, and 2026 guidance of $825M-$855M, plus a $50M buyback tranche.

Expected impact

potential modest upside as market prices in ADHD growth and buyback, tempered by profit margin pressure

Evidence & confidence

Revenue beat and strong guidance on core ADHD products outweighs GAAP profit decline; investors may bid the stock higher.

Market effects

ADHD pharmaceutical segment may see increased investor interest, benefiting peers with similar pipelines.

U.S. biotech sector could see modest lift in the day following the release.

Limited to U.S. and international investors tracking ADHD drug market trends.

Counterpoint

Profit margin compression and generic competition could pressure the stock despite revenue growth.

Key entities

  • Collegium Pharmaceutical Inc.

    U.S.-listed pharmaceutical company focusing on ADHD and pain management.

Related articles

$COLLMed

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

$COLLMed

Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

$COLLMed

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.

$COLLLow

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Genera